Owkin’s MSIntuit CRC wins the Best Medical Technology Prix Galien Award
Owkin wins the Prix Galien Award in the category of Best Medical Technology for their product, MSIntuit® CRC. This prestigious honor recognizes Owkin’s commitment to innovation and excellence in healthcare.
MSIntuit® CRC is a testament to the power of artificial intelligence in transforming healthcare. It is the first and only CE-marked AI diagnostic for MSI testing in colorectal cancer from digital H&E slides.
As the demand for MSI screening increases, pathologists and labs are facing bottlenecks and resource pressures. MSIntuit® CRC aims to streamline this biomarker testing, decrease workload and turnaround time, and preserve tissue material and resources.
Curious about MSIntuit CRC?
Owkin is partnering with MSD to develop and commercialize MSIntuit® across four additional types of cancer: endometrial, gastric, small intestine, and biliary. Learn more here
This year's winners and their pioneering solutions are driving significant advancements in patient care. These visionary leaders are paving the way for a healthier future, and it is an honour to celebrate their remarkable achievements," said Bruno Cohen, Chairman of The Galien Foundation. "With profound gratitude, we acknowledge their tireless pursuit of knowledge and the enduring legacy they are forging for generations to come."
Discover the 2024 Prix Galien UK Award Winners here
MSIntuit® CRC is a medical device for use by healthcare professionals only. This deep learning software is intended to assist pathologists in the pre-selection of patients with microsatellite phenotype (MSS) / proficient mismatch repair system (pMMR) in colorectal tumors. It identifies MSS patients from a digitized histology slide image of hematoxylin and eosin (H&E) stained colorectal tissue resection for patients with primary colorectal cancer. MSIntuit® CRC is intended to be used as an additional source of information for the pathologist when assessing MSS status and its results should not be used as the primary diagnosis. Pathologists should only use MSIntuit CRC in conjunction with their usual diagnostic criteria. MSIntuit ® CRC is CE-IVD marked for diagnostic use. The device is not FDA cleared nor approved in the United States, for use only in countries with applicable health authority registrations. Please contact Owkin to know where the product is registered and commercialized.
*For detailed information on proper use and precautions, please read carefully the instructions for use provided with the product
Images shown may represent the range of products, or be for illustration purposes only, and may not be an exact representation of the product.
Manufacturer: Owkin France. MSIntuit® CRC is a trademark of Owkin Inc. Information updated on July 2024 - Version W005V1
About Owkin
Owkin is the first full-stack TechBio company on a mission to understand complex biology and derive new multimodal biomarkers through AI.
We identify precision therapeutics, de-risk and accelerate clinical trials and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular, immunity and inflammation.
Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across seven cancer indications.
Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like F-Prime, GV and Bpifrance, among others.
